Tatva Chintan Pharma Chem Limited — PPTs, 25-10-2024: Investor Presentation

Tatva Chintan Pharma Chem Limited reported declining financial results for Q2FY25, with revenue from operations at ₹835 million, down 14% YoY, and EBITDA at ₹56 million, a 72% YoY decrease. The company faces challenges from global demand weakness and competition. However, it maintains optimism due to a robust product pipeline and ongoing R&D efforts. The company continues to focus on sustainable practices and aims for growth despite current headwinds in the specialty chemicals industry.